Fortitude Family Office’s Jazz Pharmaceuticals JAZZ Stock Holding History

Fortitude Family Office’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$37.5K	Buy	162 +34	+27%	+$8.4K	0.01%	570
2026 Q2	$30.8K	Buy	128 +68	+113%	+$14.9K	0.01%	399
2026 Q1	$11.3K	Buy	60 +27	+82%	+$4.72K	﹤0.01%	605
2025 Q4	$5.61K	Buy	33 +2	+6%	+$307	﹤0.01%	772
2025 Q3	$4.09K	Hold	31	–	–	﹤0.01%	880
2025 Q2	$3.29K	Sell	31 -6	-16%	-$652	﹤0.01%	969
2025 Q1	$4.59K	Sell	37 -6	-14%	-$783	﹤0.01%	754
2024 Q4	$5.3K	Buy	43 +37	+617%	+$4.36K	﹤0.01%	825
2024 Q3	$668	Buy	+6	New	+$657	﹤0.01%	1140

Other funds holding JAZZ

ACM

Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $6.57B AUM 14.15% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Burney Company Reston, Virginia $3.66B AUM 27.59% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

OLA

Oliver Luxxe Assets Gladstone, New Jersey $638M AUM 30.27% 1-Year Est. Return

CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return

Fortitude Family Office's JAZZ Position: Q3 2026 in Review

Fortitude Family Office increased its Jazz Pharmaceuticals (JAZZ) stake by 27% in Q3 2026, buying an estimated $8.4K and bringing the position to 162 shares worth $37.5K. The position accounts for 0.01% of the portfolio, ranked #570.

Fortitude Family Office first reported a position in JAZZ in Q3 2024 and has held it in 9 quarters since. 69 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.

Fortitude Family Office held 162 shares of Jazz Pharmaceuticals worth $37.5K as of Q3 2026.
Fortitude Family Office bought 34 Jazz Pharmaceuticals shares in Q3 2026, an estimated $8.4K.
Jazz Pharmaceuticals made up 0.01% of Fortitude Family Office's portfolio in Q3 2026, its #570 holding.
Fortitude Family Office first reported a position in Jazz Pharmaceuticals in Q3 2024 and has held it in 9 quarters since.
69 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.